Investigational Drug Information for PSN-632,408
✉ Email this page to a colleague
What is the development status for investigational drug PSN-632,408?
PSN-632,408 is an investigational drug.
There have been 7 clinical trials for PSN-632,408.
The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2020.
The most common disease conditions in clinical trials are Colorectal Neoplasms, Neurotoxicity Syndromes, and Leukemia. The leading clinical trial sponsors are Sanofi, National Cheng-Kung University Hospital, and University of Pisa.
There are sixty-one US patents protecting this investigational drug and five hundred and ninety-seven international patents.
Summary for PSN-632,408
| US Patents | 61 |
| International Patents | 597 |
| US Patent Applications | 105 |
| WIPO Patent Applications | 61 |
| Japanese Patent Applications | 5 |
| Clinical Trial Progress | Phase 3 (2020-07-01) |
| Vendors | 39 |
Recent Clinical Trials for PSN-632,408
| Title | Sponsor | Phase |
|---|---|---|
| Topical Vancomycin Over Sternal Edge in Cardiac Surgery | National Cheng-Kung University Hospital | Phase 4 |
| Ultrasound-guided Sacroiliac Joint Radiofrequency Ablation: A Pilot Study | University of Alberta | N/A |
| Ultrasound-guided Sacroiliac Joint Radiofrequency Ablation: A Pilot Study | University of Toronto | N/A |
Clinical Trial Summary for PSN-632,408
Top disease conditions for PSN-632,408
Top clinical trial sponsors for PSN-632,408
US Patents for PSN-632,408
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| PSN-632,408 | ⤷ Try a Trial | Generation of muscle lineage cells and therapeutic uses thereof | GENEA BIOCELLS USA (HOLDINGS), INC. (San Diego, CA) | ⤷ Try a Trial |
| PSN-632,408 | ⤷ Try a Trial | Modulation of cellular stress using a B-cell oxidative and/or endoplasmic reticulum stress inhibitor and a targeting agent | The University of Queensland (Queensland, AU) | ⤷ Try a Trial |
| PSN-632,408 | ⤷ Try a Trial | Phenothiazin derivatives, method for the production thereof and use thereof as pharmaceuticals | Sanofi-Aventis (Paris, FR) | ⤷ Try a Trial |
| PSN-632,408 | ⤷ Try a Trial | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use | Sanofi-Aventis (Paris, FR) | ⤷ Try a Trial |
| PSN-632,408 | ⤷ Try a Trial | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | Arena Pharmaceuticals, Inc. (San Diego, CA) | ⤷ Try a Trial |
| PSN-632,408 | ⤷ Try a Trial | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | Arena Pharmaceuticals, Inc. (San Diego, CA) | ⤷ Try a Trial |
| PSN-632,408 | ⤷ Try a Trial | GRP119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | Arena Pharmaceuticals, Inc. (San Diego, CA) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for PSN-632,408
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| PSN-632,408 | Australia | AU2017351638 | 2036-10-26 | ⤷ Try a Trial |
| PSN-632,408 | Canada | CA3044691 | 2036-10-26 | ⤷ Try a Trial |
| PSN-632,408 | China | CN110730819 | 2036-10-26 | ⤷ Try a Trial |
| PSN-632,408 | European Patent Office | EP3532605 | 2036-10-26 | ⤷ Try a Trial |
| PSN-632,408 | World Intellectual Property Organization (WIPO) | WO2018076060 | 2036-10-26 | ⤷ Try a Trial |
| PSN-632,408 | Australia | AU2015268101 | 2034-05-27 | ⤷ Try a Trial |
| PSN-632,408 | Australia | AU2021202648 | 2034-05-27 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
